Hongri Pharmaceutical's Enoxaparin Sodium Injection Approved for Marketing in the Prevention and Treatment of Thrombotic or Embolic Diseases

On January 11, Hongri Pharmaceutical issued an announcement saying that the company's enoxaparin sodium injection, which is a generic type 4 product, was approved for marketing, and it was deemed to have passed the consistency evaluation
.
As the first heparin drug that has been reviewed by three companies, the domestic market of enoxaparin sodium injection has continued to expand in recent years, with terminal sales of more than 2.

Enoxaparin sodium injection is a low molecular weight heparin, mainly used for the treatment of symptoms such as anticoagulation and antithrombosis, and for the prevention and treatment of thrombosis or embolic diseases (such as myocardial infarction, thrombophlebitis, pulmonary embolism, etc.
)
.

According to the data of Minet.
com, the domestic market of enoxaparin sodium injection has continued to expand in recent years.
In 2020, the terminal sales in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 23%.
100 million yuan, a year-on-year increase of 6.
26%; sales in the first half of 2021 exceeded 1 billion yuan, a year-on-year increase of 23.
82%
.

Sales of terminal enoxaparin sodium injection in Chinese public medical institutions (unit: ten thousand yuan)

Source: Minet.
com China's public medical institutions terminal competition pattern

For a long time, the domestic enoxaparin sodium injection market has been dominated by the original manufacturer Sanofi, with a market share of more than 50%
.
Among the domestic manufacturers, Jianyou Co.

With the official entry of Hongri Pharmaceutical, there are currently 9 manufacturers of enoxaparin sodium injection in the domestic market, including Jianyou Co.
, Ltd.
, Haipurui, Jiuyuan Gene, Qianhong Pharmaceutical, Shuanglu Pharmaceutical, Changshan Pharmaceutical, Baiyi Yu Pharmaceutical, Dongying Tiandong Pharmaceutical, and Hongri Pharmaceutical
.

At present, only two varieties of heparin drugs have been reviewed: enoxaparin sodium injection and nadroparin calcium injection
.
Nadroparin Calcium Injection is exclusively reviewed by Tianjin Pharmaceuticals, and 3 companies have reviewed Enoxaparin Sodium Injection, including Hepalink, Qianhong Pharmaceutical, and Hongri Pharmaceutical

Whether enoxaparin sodium injection will be included in the upcoming seventh batch of centralized collection is worthy of attention

Data source: Minet database